The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia

被引：2

作者：

Costa, Alessandro ^{[1
]}

Pittorru, Raimondo ^{[2
]}

Caocci, Giovanni ^{[1
]}

Migliore, Federico ^{[2
]}

Tona, Francesco ^{[2
]}

Mulas, Olga ^{[1
]}

La Nasa, Giorgio ^{[1
]}

机构：

[1] Univ Cagliari, Businco Hosp, Dept Med Sci & Publ Hlth, Hematol Unit, I-09121 Cagliari, Italy

[2] Univ Padua, Dept Cardiac Thorac Vasc & Publ Hlth, I-35100 Padua, Italy

来源：

HEMATO | 2023年 / 4卷 / 03期

关键词：

TKI; cardiovascular toxicity; CML; ADVERSE EVENTS; IMATINIB MESYLATE; LIPID-METABOLISM; RISK-FACTORS; DASATINIB; NILOTINIB; PONATINIB; DISEASE; IMPACT; IDENTIFICATION;

D O I：

10.3390/hemato4030017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since their introduction, tyrosine kinase inhibitors (TKIs) have radically changed the treatment paradigm of Chronic Myeloid Leukemia (CML), leading to deep and lasting molecular responses and profoundly influencing survival. However, cancer-therapy-related Cardiovascular Toxicities (CTR-CVTs) associated with BCR::ABL1 TKIs are one of the main sources of concern: hypertension, arterial occlusive events, arrhythmias, dysmetabolic alteration, and glomerular filtration impairment are frequently reported in clinical trials and real-life experiences. Therefore, a close interaction between hematologists and cardiologists becomes crucial to implementing prevention protocols based on a comprehensive assessment of baseline cardiovascular risk, the management of any detectable and modifiable risk factors, and the elaboration of a monitoring plan for CTR-CVTs during treatment. Here, we provide the most comprehensive and recent evidence in the literature on the pathophysiological patterns underlying CTR-CVTs, providing useful evidence-based guidance on the prevention and management of CVD risk factors at baseline and during treatment with BCR::ABL1 TKIs.

引用

页码：207 / 226

页数：20

共 129 条

[1] Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy [J].

Abumiya, Maiko ;

Takahashi, Naoto ;

Takahashi, Saori ;

Yoshioka, Tomoko ;

Kameoka, Yoshihiro ;

Miura, Masatomo .

SCIENTIFIC REPORTS, 2021, 11 (01)

[2]

Agostino Nicole M, 2011, J Oncol Pharm Pract, V17, P197, DOI 10.1177/1078155210378913

[3] Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia [J].

Al-Kali, A. ;

Farooq, S. ;

Tfayli, A. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2009, 34 (05) :607-610

[4] The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state [J].

Alhawiti, Naif ;

Burbury, Kate L. ;

Kwa, Faith A. ;

O'Malley, Cindy J. ;

Shuttleworth, Peter ;

Alzard, Mohamad ;

Hamadi, Abdullah ;

Grigg, Andrew P. ;

Jackson, Denise E. .

THROMBOSIS RESEARCH, 2016, 145 :54-64

[5]

[Anonymous], 2023, EUR HEART J, V44, P1312, DOI [10.1093/eurheartj/ehad005, 10.1183/13993003.00879-2022, 10.1093/eurheartj/ehac237]

[6]

[Anonymous], 2013, Kidney International Supplements, V3, P19, DOI DOI 10.1038/KISUP.2012.64

[7]

[Anonymous], Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society-PubMed

[8] Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [J].